Cargando…

Injection of hydrogel spacer increased maximal intrafractional prostate motion in anterior and superior directions during volumetric modulated arc therapy-stereotactic body radiation therapy for prostate cancer

BACKGROUND: The aim of this study was to clarify the association between intrafractional prostate shift and hydrogel spacer. METHODS: Thirty-eight patients who received definitive volumetric modulated arc therapy (VMAT)-stereotactic body radiation therapy (SBRT) for prostate cancer with prostate mot...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawayanagi, Subaru, Yamashita, Hideomi, Ogita, Mami, Takenaka, Ryosuke, Nozawa, Yuki, Watanabe, Yuichi, Imae, Toshikazu, Abe, Osamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867734/
https://www.ncbi.nlm.nih.gov/pubmed/35197092
http://dx.doi.org/10.1186/s13014-022-02008-3
_version_ 1784656115187843072
author Sawayanagi, Subaru
Yamashita, Hideomi
Ogita, Mami
Takenaka, Ryosuke
Nozawa, Yuki
Watanabe, Yuichi
Imae, Toshikazu
Abe, Osamu
author_facet Sawayanagi, Subaru
Yamashita, Hideomi
Ogita, Mami
Takenaka, Ryosuke
Nozawa, Yuki
Watanabe, Yuichi
Imae, Toshikazu
Abe, Osamu
author_sort Sawayanagi, Subaru
collection PubMed
description BACKGROUND: The aim of this study was to clarify the association between intrafractional prostate shift and hydrogel spacer. METHODS: Thirty-eight patients who received definitive volumetric modulated arc therapy (VMAT)-stereotactic body radiation therapy (SBRT) for prostate cancer with prostate motion monitoring in our institution in 2018–2019 were retrospectively evaluated. In order to move the rectum away from the prostate, hydrogel spacer (SpaceOAR system, Boston Scientific, Marlborough, the United States) injection was proposed to the patients as an option in case of meeting the indication of use. We monitored intrafractional prostate motion by using a 4-dimensional (4D) transperineal ultrasound device: the Clarity 4D ultrasound system (Elekta AB). The deviation of the prostate was monitored in each direction: superior-inferior, left–right, and anterior–posterior. We also calculated the vector length. The maximum intrafractional displacement (MID) per fraction for each direction was detected and mean of MIDs was calculated per patient. The MIDs in the non-spacer group and the spacer group were compared using the unpaired t-test. RESULTS: We reviewed 33 fractions in eight patients as the spacer group and 148 fractions in 30 patients as the non-spacer group. The superior MID was 0.47 ± 0.07 (mean ± SE) mm versus 0.97 ± 0.24 mm (P = 0.014), the inferior MID was 1.07 ± 0.11 mm versus 1.03 ± 0.25 mm (P = 0.88), the left MID was 0.74 ± 0.08 mm versus 0.87 ± 0.27 mm (P = 0.55), the right MID was 0.67 ± 0.08 mm versus 0.92 ± 0.21 mm (P = 0.17), the anterior MID was 0.45 ± 0.06 mm versus 1.16 ± 0.35 mm (P = 0.0023), and the posterior MID was 1.57 ± 0.17 mm versus 1.37 ± 0.22 mm (P = 0.56) in the non-spacer group and the spacer group, respectively. The max of VL was 2.24 ± 0.19 mm versus 2.89 ± 0.62 mm (P = 0.19), respectively. CONCLUSIONS: Our findings suggest that maximum intrafractional prostate motion during VMAT-SBRT was larger in patients with hydrogel spacer injection in the superior and anterior directions. Since this difference seemed not to disturb the dosimetric advantage of the hydrogel spacer, we do not recommend routine avoidance of the hydrogel spacer use.
format Online
Article
Text
id pubmed-8867734
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88677342022-02-25 Injection of hydrogel spacer increased maximal intrafractional prostate motion in anterior and superior directions during volumetric modulated arc therapy-stereotactic body radiation therapy for prostate cancer Sawayanagi, Subaru Yamashita, Hideomi Ogita, Mami Takenaka, Ryosuke Nozawa, Yuki Watanabe, Yuichi Imae, Toshikazu Abe, Osamu Radiat Oncol Research BACKGROUND: The aim of this study was to clarify the association between intrafractional prostate shift and hydrogel spacer. METHODS: Thirty-eight patients who received definitive volumetric modulated arc therapy (VMAT)-stereotactic body radiation therapy (SBRT) for prostate cancer with prostate motion monitoring in our institution in 2018–2019 were retrospectively evaluated. In order to move the rectum away from the prostate, hydrogel spacer (SpaceOAR system, Boston Scientific, Marlborough, the United States) injection was proposed to the patients as an option in case of meeting the indication of use. We monitored intrafractional prostate motion by using a 4-dimensional (4D) transperineal ultrasound device: the Clarity 4D ultrasound system (Elekta AB). The deviation of the prostate was monitored in each direction: superior-inferior, left–right, and anterior–posterior. We also calculated the vector length. The maximum intrafractional displacement (MID) per fraction for each direction was detected and mean of MIDs was calculated per patient. The MIDs in the non-spacer group and the spacer group were compared using the unpaired t-test. RESULTS: We reviewed 33 fractions in eight patients as the spacer group and 148 fractions in 30 patients as the non-spacer group. The superior MID was 0.47 ± 0.07 (mean ± SE) mm versus 0.97 ± 0.24 mm (P = 0.014), the inferior MID was 1.07 ± 0.11 mm versus 1.03 ± 0.25 mm (P = 0.88), the left MID was 0.74 ± 0.08 mm versus 0.87 ± 0.27 mm (P = 0.55), the right MID was 0.67 ± 0.08 mm versus 0.92 ± 0.21 mm (P = 0.17), the anterior MID was 0.45 ± 0.06 mm versus 1.16 ± 0.35 mm (P = 0.0023), and the posterior MID was 1.57 ± 0.17 mm versus 1.37 ± 0.22 mm (P = 0.56) in the non-spacer group and the spacer group, respectively. The max of VL was 2.24 ± 0.19 mm versus 2.89 ± 0.62 mm (P = 0.19), respectively. CONCLUSIONS: Our findings suggest that maximum intrafractional prostate motion during VMAT-SBRT was larger in patients with hydrogel spacer injection in the superior and anterior directions. Since this difference seemed not to disturb the dosimetric advantage of the hydrogel spacer, we do not recommend routine avoidance of the hydrogel spacer use. BioMed Central 2022-02-23 /pmc/articles/PMC8867734/ /pubmed/35197092 http://dx.doi.org/10.1186/s13014-022-02008-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Sawayanagi, Subaru
Yamashita, Hideomi
Ogita, Mami
Takenaka, Ryosuke
Nozawa, Yuki
Watanabe, Yuichi
Imae, Toshikazu
Abe, Osamu
Injection of hydrogel spacer increased maximal intrafractional prostate motion in anterior and superior directions during volumetric modulated arc therapy-stereotactic body radiation therapy for prostate cancer
title Injection of hydrogel spacer increased maximal intrafractional prostate motion in anterior and superior directions during volumetric modulated arc therapy-stereotactic body radiation therapy for prostate cancer
title_full Injection of hydrogel spacer increased maximal intrafractional prostate motion in anterior and superior directions during volumetric modulated arc therapy-stereotactic body radiation therapy for prostate cancer
title_fullStr Injection of hydrogel spacer increased maximal intrafractional prostate motion in anterior and superior directions during volumetric modulated arc therapy-stereotactic body radiation therapy for prostate cancer
title_full_unstemmed Injection of hydrogel spacer increased maximal intrafractional prostate motion in anterior and superior directions during volumetric modulated arc therapy-stereotactic body radiation therapy for prostate cancer
title_short Injection of hydrogel spacer increased maximal intrafractional prostate motion in anterior and superior directions during volumetric modulated arc therapy-stereotactic body radiation therapy for prostate cancer
title_sort injection of hydrogel spacer increased maximal intrafractional prostate motion in anterior and superior directions during volumetric modulated arc therapy-stereotactic body radiation therapy for prostate cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867734/
https://www.ncbi.nlm.nih.gov/pubmed/35197092
http://dx.doi.org/10.1186/s13014-022-02008-3
work_keys_str_mv AT sawayanagisubaru injectionofhydrogelspacerincreasedmaximalintrafractionalprostatemotioninanteriorandsuperiordirectionsduringvolumetricmodulatedarctherapystereotacticbodyradiationtherapyforprostatecancer
AT yamashitahideomi injectionofhydrogelspacerincreasedmaximalintrafractionalprostatemotioninanteriorandsuperiordirectionsduringvolumetricmodulatedarctherapystereotacticbodyradiationtherapyforprostatecancer
AT ogitamami injectionofhydrogelspacerincreasedmaximalintrafractionalprostatemotioninanteriorandsuperiordirectionsduringvolumetricmodulatedarctherapystereotacticbodyradiationtherapyforprostatecancer
AT takenakaryosuke injectionofhydrogelspacerincreasedmaximalintrafractionalprostatemotioninanteriorandsuperiordirectionsduringvolumetricmodulatedarctherapystereotacticbodyradiationtherapyforprostatecancer
AT nozawayuki injectionofhydrogelspacerincreasedmaximalintrafractionalprostatemotioninanteriorandsuperiordirectionsduringvolumetricmodulatedarctherapystereotacticbodyradiationtherapyforprostatecancer
AT watanabeyuichi injectionofhydrogelspacerincreasedmaximalintrafractionalprostatemotioninanteriorandsuperiordirectionsduringvolumetricmodulatedarctherapystereotacticbodyradiationtherapyforprostatecancer
AT imaetoshikazu injectionofhydrogelspacerincreasedmaximalintrafractionalprostatemotioninanteriorandsuperiordirectionsduringvolumetricmodulatedarctherapystereotacticbodyradiationtherapyforprostatecancer
AT abeosamu injectionofhydrogelspacerincreasedmaximalintrafractionalprostatemotioninanteriorandsuperiordirectionsduringvolumetricmodulatedarctherapystereotacticbodyradiationtherapyforprostatecancer